{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T21:45:23Z","timestamp":1789854323440,"version":"4.0.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["L'Enc\u00e9phale"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1016\/j.encep.2009.10.008","type":"journal-article","created":{"date-parts":[[2009,12,2]],"date-time":"2009-12-02T09:24:21Z","timestamp":1259745861000},"page":"242-252","source":"Crossref","is-referenced-by-count":19,"title":["Effets secondaires m\u00e9taboliques de la risp\u00e9ridone dans les schizophr\u00e9nies \u00e0 d\u00e9but pr\u00e9coce"],"prefix":"10.1016","volume":"36","author":[{"given":"J.-L.","family":"Goeb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Marco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Duhamel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Kechid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Bordet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Delion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Jardri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.encep.2009.10.008_bib1","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1176\/ajp.156.11.1686","article-title":"Antipsychotic-induced weight gain: a comprehensive research synthesis","volume":"156","author":"Allison","year":"1999","journal-title":"Am J Psychiatry"},{"issue":"4","key":"10.1016\/j.encep.2009.10.008_bib2","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1176\/appi.ps.54.4.565","article-title":"The impact of weight gain on quality of life among persons with schizophrenia","volume":"54","author":"Allison","year":"2003","journal-title":"Psychiatr Serv"},{"key":"10.1016\/j.encep.2009.10.008_bib3","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1176\/appi.ajp.159.8.1337","article-title":"Risperidone Disruptive Behavior Study G*roup. Double-blind, placebo-controlled study of risperidone for treatment of disruptive behaviors in children with subaverage intelligence","volume":"159","author":"Aman","year":"2002","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.encep.2009.10.008_bib4","doi-asserted-by":"crossref","first-page":"267","DOI":"10.4088\/JCP.v65n0219","article-title":"Consensus development conference on antipsychotic drugs and obesity and diabetes","volume":"65","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.encep.2009.10.008_bib5","unstructured":"ANAES. Prise en charge de l\u2019ob\u00e9sit\u00e9 de l\u2019enfant et de l\u2019adolescent. 2003."},{"issue":"3","key":"10.1016\/j.encep.2009.10.008_bib6","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1089\/cap.2004.14.372","article-title":"Second-generation antipsychotic medications in children and adolescents. J Child","volume":"14","author":"Cheng-Shannon","year":"2004","journal-title":"Adolesc Psychopharmacol"},{"issue":"Suppl. 8","key":"10.1016\/j.encep.2009.10.008_bib7","first-page":"36","article-title":"New-onset dyslipidemia in antipsychotic-naive youngsters treated with atypical antipsychotics","volume":"57","author":"Corell","year":"2005","journal-title":"Biol Psychiatry"},{"issue":"Suppl. 8","key":"10.1016\/j.encep.2009.10.008_bib8","first-page":"36","article-title":"Body composition changes associated with second-generation antipsychotics","volume":"57","author":"Correll","year":"2005","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.encep.2009.10.008_bib9","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.chc.2005.08.007","article-title":"Recognizing and monitoring Adverse Events of Second-Generation Antipsychotics in Children and Adolescents","volume":"15","author":"Correll","year":"2006","journal-title":"Child Adolesc Psychiatric Clin N Am"},{"issue":"2","key":"10.1016\/j.encep.2009.10.008_bib10","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s00702-006-0602-7","article-title":"Weight gain associated with clozapine, olanzapine and risperidone in children and adolescents","volume":"114","author":"Fleischhaker","year":"2007","journal-title":"J Neural Transm"},{"key":"10.1016\/j.encep.2009.10.008_bib11","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1176\/appi.ajp.159.6.1055","article-title":"A. Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine","volume":"159","author":"Gothelf","year":"2002","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.encep.2009.10.008_bib12","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1089\/10445460152595559","article-title":"Weight gain in a controlled study of risperidone in children, adolescents and adults with mental retardation and autism. J Child","volume":"11","author":"Hellings","year":"2001","journal-title":"Adolesc Psychopharmacol"},{"issue":"4","key":"10.1016\/j.encep.2009.10.008_bib13","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/sj.mp.4001968","article-title":"An 11\u00a0year-old boy with drug resistant schizophrenia treated with temporo-parietal rTMS","volume":"12","author":"Jardri","year":"2007","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.encep.2009.10.008_bib14","unstructured":"Kechid G., Goeb J.-L., Lema\u00eetre V., et al. Ob\u00e9sit\u00e9 infantile\u00a0: aspects cliniques, psychopathologiques et th\u00e9rapeutiques. Paris: EMC (Elsevier Masson SAS, Paris), Psychiatrie\/P\u00e9dopsychiatrie, 37\u2013201-A-25, 2009."},{"key":"10.1016\/j.encep.2009.10.008_bib15","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1089\/cap.1998.8.151","article-title":"Weight gain in adolescents treated with risperidone and conventional antipsychotics over six months. J Child","volume":"8","author":"Kelly","year":"1998","journal-title":"Adolesc Psychopharmacol"},{"key":"10.1016\/j.encep.2009.10.008_bib16","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1176\/appi.ajp.160.2.290","article-title":"Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics","volume":"160","author":"Lindenmayer","year":"2003","journal-title":"Am J Psychiatry"},{"issue":"3","key":"10.1016\/j.encep.2009.10.008_bib17","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00787-002-0255-5","article-title":"Triglyceride, cholesterol and weight changes among risperidone-treated youths. A retrospective study","volume":"11","author":"Martin","year":"2002","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"10.1016\/j.encep.2009.10.008_bib18","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1089\/cap.2000.10.259","article-title":"Risperidone-associated weight gain in children and adolescents: a retrospective chart review. J Child","volume":"10","author":"Martin","year":"2000","journal-title":"Adolesc Psychopharmacol"},{"issue":"12","key":"10.1016\/j.encep.2009.10.008_bib19","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1016\/j.clinthera.2004.12.003","article-title":"Metabolic risk during antipsychotic treatment","volume":"26","author":"Newcomer","year":"2004","journal-title":"Clin Ther"},{"key":"10.1016\/j.encep.2009.10.008_bib20","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1097\/00004583-200205000-00008","article-title":"National trends in the use of psychotropic medications by children","volume":"41","author":"Olfson","year":"2002","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.encep.2009.10.008_bib21","first-page":"47","article-title":"Comite de nutrition de la Soci\u00e9t\u00e9 Fran\u00e7aise de p\u00e9diatrie","volume":"16","author":"Onis","year":"2009","journal-title":"Arch Ped"},{"issue":"4","key":"10.1016\/j.encep.2009.10.008_bib22","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.chc.2004.04.007","article-title":"A review of the growing evidence base for pediatric psychopharmacology","volume":"13","author":"Papadopulos","year":"2004","journal-title":"Child Adolesc Psychiatr Clin N Am"},{"key":"10.1016\/j.encep.2009.10.008_bib23","series-title":"The schedule for affective disorders and schizophrenia for school-age children (Kiddie-Sads)","author":"Puig-Antich","year":"1978"},{"issue":"3","key":"10.1016\/j.encep.2009.10.008_bib24","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/00004583-200203000-00014","article-title":"Weight gain associated with olanzapine and risperidone in adolescents patients: a comparative prospective study","volume":"41","author":"Ratzoni","year":"2002","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.encep.2009.10.008_bib25","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJMoa013171","article-title":"Risperidone in children with autism and serious behavioral problems","volume":"347","year":"2002","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.encep.2009.10.008_bib26","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1097\/01.jcp.0000130558.86125.5b","article-title":"A comparison of risperidone-induced weight gain across the age span","volume":"24","author":"Safer","year":"2004","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"10.1016\/j.encep.2009.10.008_bib27","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/sj.npp.1300327","article-title":"A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial","volume":"29","author":"Sikich","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.encep.2009.10.008_bib28","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1097\/00004583-200209000-00002","article-title":"Risperidone Conduct Study Group. Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs","volume":"41","author":"Snyder","year":"2002","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"1","key":"10.1016\/j.encep.2009.10.008_bib29","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1089\/cap.2005.15.57","article-title":"Current prescribing patterns in outpatient child and adolescent practice in Central New York. J Child","volume":"15","author":"Staller","year":"2005","journal-title":"Adolesc Psychopharmacol"},{"issue":"1","key":"10.1016\/j.encep.2009.10.008_bib30","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2165\/00148581-200406010-00003","article-title":"Weight gain associated with atypical antipsychotic use in children and adolescents: prevalence, clinical relevance, and management","volume":"6","author":"Stigler","year":"2004","journal-title":"Pediatric Drugs"},{"key":"10.1016\/j.encep.2009.10.008_bib31","doi-asserted-by":"crossref","first-page":"644","DOI":"10.4088\/JCP.v59n1202","article-title":"Use of atypical neuroleptics in child and adolescent psychiatry","volume":"59","author":"Toren","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.encep.2009.10.008_bib32","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1600-0447.2004.00444.x","article-title":"Newer antipsychotic drugs and obesity in children and adolescents. How should we assess drug-associated weight gain ?","volume":"111","author":"Vieweg","year":"2005","journal-title":"Acta Psychiatr Scand"},{"issue":"23","key":"10.1016\/j.encep.2009.10.008_bib33","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1056\/NEJMoa031049","article-title":"Obesity and the metabolic syndrome in children and adolescents","volume":"350","author":"Weiss","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.encep.2009.10.008_bib34","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1089\/104454603322572651","article-title":"Effectiveness, safety, and tolerability of risperidone in adolescents with schizophrenia: an open-label study","volume":"13","author":"Zalsman","year":"2003","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"1","key":"10.1016\/j.encep.2009.10.008_bib35","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1001\/archpedi.157.1.17","article-title":"Psychotropic practice patterns for youth: a 10-year perspective","volume":"157","author":"Zito","year":"2003","journal-title":"Arch Pediatr Adolesc Med"}],"container-title":["L'Enc\u00e9phale"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0013700609002188?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0013700609002188?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,27]],"date-time":"2023-05-27T19:09:44Z","timestamp":1685214584000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0013700609002188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["S0013700609002188"],"URL":"https:\/\/doi.org\/10.1016\/j.encep.2009.10.008","relation":{},"ISSN":["0013-7006"],"issn-type":[{"value":"0013-7006","type":"print"}],"subject":[],"published":{"date-parts":[[2010,6]]}}}